Home Technology Pipeline Our Team Contact Us
Developing Next Generation for the treatment of Central Nervous Disorders

Stress, Mood, and Behavioral Disorders

Intermittent Explosive Disorder severely impacts quality of life and poses substantial risk to patients. Current estimates indicate up to 6% lifetime prevalence in the US alone. There are currently no approved treatments.

Neuropsychiatric Symptoms in Huntingtonís Disease. Irritability and aggression are commonly observed in a high percentage of HD patients. These neuropsychiatric manifestations of HD are difficult to treat with existing pharmacologic and behavioral approaches and have major effects on the quality of life of HD subjects and their families.

Post-Traumatic Stress Disorder (PTSD) is the most rapidly growing psychiatric diagnosis in the United States and a major issue for military medicine. Current treatments are repurposed drugs that are minimally effective.

Anger/Aggression/Impulse Control Disorders are common co-morbidities impacting therapeutic response in multiple indications, including TBI, ADHD, PTSD, and personality disorders. There are currently no approved treatments.

Major Depression and Treatment Resistant Depression (TRD). Some 50% of patients do not respond to current drug therapies; A novel, non-monoamine mechanism of action provides differentiation and an opportunity to address TRD.

Azevan Pharmaceuticals is a clinical stage, small molecule drug development company developing novel therapeutics to treat disorders of stress, mood, and behavior. The Companyís first clinical compounds selectively block the effects of arginine vasopressin, a peptide neurohormone involved in the pathophysiology of Intermittent Explosive Disorder, neuropsychiatric symptoms in neurodegenerative diseases, PTSD, and other affective disorders. Vasopressin 1a receptor antagonists represent a novel mechanism of action for addressing these indications.

A 12 week Phase II Clinical Trial with SRX246 for the treatment of Intermittent Explosive Disorder launched in Q2 2014. Additional Phase II studies are planned in other indications.

Azevan facts
  • A Phase II clinical trial with SRX246 for the treatment of Intermittent Explosive Disorder launched in April 2014.
  • SRX251, a second clinical candidate, is being developed for TBI and other indications.
  • Azevanís library is based on proprietary azetidinone chemistry that can be manipulated to target additional high-value GPCRs.
  • Venture-backed company founded and run by experienced chemists and neurobiologists.